Bio-pharmaceutical company NeuroSearch A/S (CPH:NEUR) reported on Thursday the receipt of a major shareholder announcement from Glaxo Group Limited.

Under this announcement, Glaxo Group Limited has informed NeuroSearch that Glaxo Group Limited has disposed of all of its shares in NeuroSearch.

Now, following this, Glaxo Group Limited does not hold any shares or voting rights in NeuroSearch.

NeuroSearch researches and develops compounds for the treatment for diseases of the central nervous system such as Huntington's disease, attention deficit disorder, schizophrenia, dyskinesias, cognitive dysfunctions, depression and anxiety and social anxiety disorder. NeuroSearch also researches treatments for obesity.